MELK and lymphoma: Consistent with this hypothesis, combining OTSSP167 with venetoclax significantly and highly synergistically enhances the anti-lymphoma effects of the MELK inhibitor in all cell lines tested, even in the highly venetoclax-sensitive ABC-DLBCL cell line U2932.